Table 1 Patient sub-groups in TRIMARAN and TRIGGER (intention-to-treat population)
TRIMARAN | TRIGGER | |||
|---|---|---|---|---|
BDP/FF/G 100/6/10 µg (N = 575) | BDP/FF 100/6 µg (N = 574) | BDP/FF/G 200/6/10 µg (N = 571) | BDP/FF 200/6 µg (N = 571) | |
Age, n (%) | ||||
< 65 years | 469 (81.6) | 476 (82.9) | 473 (82.8) | 448 (78.5) |
≥ 65 years | 106 (18.4) | 98 (17.1) | 98 (17.2) | 123 (21.5) |
Sex, n (%) | ||||
Male | 221 (38.4) | 221 (38.5) | 212 (37.1) | 244 (42.7) |
Female | 354 (61.6) | 353 (61.5) | 359 (62.9) | 327 (57.3) |
Body mass index, n (%) | ||||
< 25 kg/m2 | 172 (29.9) | 173 (30.1) | 150 (26.3) | 163 (28.5) |
25–30 kg/m2 | 230 (40.0) | 231 (40.2) | 217 (38.0) | 205 (35.9) |
≥ 30 kg/m2 | 173 (30.1) | 170 (29.6) | 204 (35.7) | 203 (35.6) |
Smoking status | ||||
Non-smoker | 483 (84.0) | 498 (86.8) | 488 (85.5) | 491 (86.0) |
Ex-smoker | 92 (16.0) | 76 (13.2) | 83 (14.5) | 80 (14.0) |
Asthma exacerbations in previous year | ||||
1 | 473 (82.3) | 473 (82.4) | 439 (76.9) | 451 (79.0) |
> 1 | 102 (17.7) | 101 (17.6) | 132 (23.1) | 120 (21.0) |
Reversibility | ||||
200–400 mL | 259 (45.0) | 279 (48.6) | 299a (52.4) | 281 (49.2) |
> 400 mL | 316 (55.0) | 295 (51.4) | 271 (47.5) | 290 (50.8) |
Eosinophils | ||||
≤ 300 cells/µL | 345 (60.0) | 351 (61.1) | 334a (58.5) | 360a (63.0) |
> 300 cells/µL | 230 (40.0) | 223 (38.9) | 236 (41.3) | 210 (36.8) |